Lack of association of tumor-associated macrophages with clinical outcome in patients with classical hodgkin's lymphoma

D. Azambuja, Y. Natkunam, I. Biasoli, Izidore Lossos, M. W. Anderson, J. C. Morais, N. Spector

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Background: A recent study demonstrated that an increased number of CD68+ macrophages were correlated with primary treatment failure, shortened progression-free survival (PFS) and disease-specific survival (DSS) in patients with classical Hodgkin's lymphoma (cHL). Patients and methods: The aim of the present study was to verify the relationship between the number of CD68+ and CD163+ macrophages with clinical outcomes in a cohort of 265 well-characterized patients with cHL treated uniformly with the standard doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy regimen. Two pairs of hematopathologists carried out independent pathological evaluations of tissue microarray slides. Results: There were no associations between clinical characteristics and the expression of CD68 or CD163. However, higher levels of CD68 and CD163 expression were correlated with the presence of Epstein-Barr virus-positive Hodgkin tumor cells (P = 0.01 and 0.037, respectively). The expression of CD68 or CD163 was not associated with either the PFS or the DSS. Conclusion: CD68 and CD163 expression require further evaluation before their use can be recommended for prognostic stratification of patients with cHL.

Original languageEnglish
Pages (from-to)736-742
Number of pages7
JournalAnnals of Oncology
Volume23
Issue number3
DOIs
StatePublished - Mar 1 2012

Fingerprint

Hodgkin Disease
Macrophages
Disease-Free Survival
Neoplasms
Dacarbazine
Survival
Vinblastine
Bleomycin
Treatment Failure
Human Herpesvirus 4
Doxorubicin
Drug Therapy

Keywords

  • CD68
  • Hodgkin's lymphoma
  • Macrophages
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Lack of association of tumor-associated macrophages with clinical outcome in patients with classical hodgkin's lymphoma. / Azambuja, D.; Natkunam, Y.; Biasoli, I.; Lossos, Izidore; Anderson, M. W.; Morais, J. C.; Spector, N.

In: Annals of Oncology, Vol. 23, No. 3, 01.03.2012, p. 736-742.

Research output: Contribution to journalArticle

Azambuja, D. ; Natkunam, Y. ; Biasoli, I. ; Lossos, Izidore ; Anderson, M. W. ; Morais, J. C. ; Spector, N. / Lack of association of tumor-associated macrophages with clinical outcome in patients with classical hodgkin's lymphoma. In: Annals of Oncology. 2012 ; Vol. 23, No. 3. pp. 736-742.
@article{3615743c6815498aae9d6d316e56457e,
title = "Lack of association of tumor-associated macrophages with clinical outcome in patients with classical hodgkin's lymphoma",
abstract = "Background: A recent study demonstrated that an increased number of CD68+ macrophages were correlated with primary treatment failure, shortened progression-free survival (PFS) and disease-specific survival (DSS) in patients with classical Hodgkin's lymphoma (cHL). Patients and methods: The aim of the present study was to verify the relationship between the number of CD68+ and CD163+ macrophages with clinical outcomes in a cohort of 265 well-characterized patients with cHL treated uniformly with the standard doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy regimen. Two pairs of hematopathologists carried out independent pathological evaluations of tissue microarray slides. Results: There were no associations between clinical characteristics and the expression of CD68 or CD163. However, higher levels of CD68 and CD163 expression were correlated with the presence of Epstein-Barr virus-positive Hodgkin tumor cells (P = 0.01 and 0.037, respectively). The expression of CD68 or CD163 was not associated with either the PFS or the DSS. Conclusion: CD68 and CD163 expression require further evaluation before their use can be recommended for prognostic stratification of patients with cHL.",
keywords = "CD68, Hodgkin's lymphoma, Macrophages, Prognosis",
author = "D. Azambuja and Y. Natkunam and I. Biasoli and Izidore Lossos and Anderson, {M. W.} and Morais, {J. C.} and N. Spector",
year = "2012",
month = "3",
day = "1",
doi = "10.1093/annonc/mdr157",
language = "English",
volume = "23",
pages = "736--742",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Lack of association of tumor-associated macrophages with clinical outcome in patients with classical hodgkin's lymphoma

AU - Azambuja, D.

AU - Natkunam, Y.

AU - Biasoli, I.

AU - Lossos, Izidore

AU - Anderson, M. W.

AU - Morais, J. C.

AU - Spector, N.

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Background: A recent study demonstrated that an increased number of CD68+ macrophages were correlated with primary treatment failure, shortened progression-free survival (PFS) and disease-specific survival (DSS) in patients with classical Hodgkin's lymphoma (cHL). Patients and methods: The aim of the present study was to verify the relationship between the number of CD68+ and CD163+ macrophages with clinical outcomes in a cohort of 265 well-characterized patients with cHL treated uniformly with the standard doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy regimen. Two pairs of hematopathologists carried out independent pathological evaluations of tissue microarray slides. Results: There were no associations between clinical characteristics and the expression of CD68 or CD163. However, higher levels of CD68 and CD163 expression were correlated with the presence of Epstein-Barr virus-positive Hodgkin tumor cells (P = 0.01 and 0.037, respectively). The expression of CD68 or CD163 was not associated with either the PFS or the DSS. Conclusion: CD68 and CD163 expression require further evaluation before their use can be recommended for prognostic stratification of patients with cHL.

AB - Background: A recent study demonstrated that an increased number of CD68+ macrophages were correlated with primary treatment failure, shortened progression-free survival (PFS) and disease-specific survival (DSS) in patients with classical Hodgkin's lymphoma (cHL). Patients and methods: The aim of the present study was to verify the relationship between the number of CD68+ and CD163+ macrophages with clinical outcomes in a cohort of 265 well-characterized patients with cHL treated uniformly with the standard doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy regimen. Two pairs of hematopathologists carried out independent pathological evaluations of tissue microarray slides. Results: There were no associations between clinical characteristics and the expression of CD68 or CD163. However, higher levels of CD68 and CD163 expression were correlated with the presence of Epstein-Barr virus-positive Hodgkin tumor cells (P = 0.01 and 0.037, respectively). The expression of CD68 or CD163 was not associated with either the PFS or the DSS. Conclusion: CD68 and CD163 expression require further evaluation before their use can be recommended for prognostic stratification of patients with cHL.

KW - CD68

KW - Hodgkin's lymphoma

KW - Macrophages

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84857534118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857534118&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdr157

DO - 10.1093/annonc/mdr157

M3 - Article

C2 - 21602260

AN - SCOPUS:84857534118

VL - 23

SP - 736

EP - 742

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 3

ER -